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Introduction References Additional Sources 
Signs and Symptoms 
. 
Patients presenting with TTP can exhibit many different symptoms due to the 
pathological processes of TTP. Classically, thrombocytopenia, microangiopathic 
hemolytic anemia, renal impairment, neurological impairment, and fever are 
seen, although not necessarily all together (Strecker-McGraw & Mark Andrew, 
2011). Bleeding, petechiae, purpura, and ecchymosis related to 
thrombocytopenia can occur as well as jaundice or dark urine related to 
hemolytic anemia. Abdominal pain, chest pain, and neurological symptoms can 
present as a result of organ damage and microvascular thrombi (Kappler et al., 
2014).  Lab values will show anemia and thrombocytopenia with platelet counts 
typically between 20 and 50,000/mm3 (Kappler et al., 2014). The reticulocyte 
count may be elevated and schistocytes can be seen on peripheral smear. 
Hemolytic anemia will cause a decreased haptoglobin, elevated reticulocyte 
count, elevated LDH, and an elevated indirect bilirubin from intravascular 
hemolysis. Coagulation studies will be normal, differentiating TTP from 
disseminated intravascular coagulation or DIC. Kidney injury may be seen on a 
basic metabolic panel but is typically more severe in HUS (Kappler et al., 2014, 
Strecker-McGraw & Mark Andrew, 2011). Some patients will present with chest 
pain and elevated troponin levels thought to be related to thrombosis of the 
coronary vasculature and should have cardiac monitoring and enzyme levels to 
monitor for cardiac impairment (Kappler et al., 2014, Strobel, Gingold, & 
Calvello, 2014). The presenting signs and symptoms can vary in patients with TTP 
but current guidelines suggest treatment for TTP be initiated in patients with 
thrombocytopenia, and microangiopathic hemolytic anemia without other 
explanation (Strobel et al., 2014) 
 
Patients with Thrombotic 
Thrombocytopenia Purpura, or TTP, are 
often times seen in the emergency 
department and subsequently admitted to 
the inpatient or the critical care unit. The 
problems that TTP patients can present 
with vary greatly and astute nursing 
assessment plus knowledge of the 
pathophysiology behind the diagnosis is 
vital to deliver excellent nursing care. 
Thrombotic Thrombocytopenia Purpura or 
TTP is a rare but potentially fatal condition 
that occurs as result of decreased levels of 
ADAMTS-13, a cleaving protease for von 
Willebrand factor (vWF), which causes 
platelet aggregation and microvascular 
thrombi and subsequent end-organ 
damage, along with thrombocytopenia, 
hemolytic anemia, and possible neurologic 
and renal impairment (Kappler, Ronan-
Bentle, & Graham, 2014). TTP belongs to a 
group of disorders called thrombotic 
microangiopathies. Also included in this 
group are Hemolytic Uremic Syndrome 
(HUS), and pregnancy-induced hemolysis, 
elevated liver enzymes, and low platelet 
count (HELLP) syndrome (Kappler et al., 
2014).  The decreases in ADAMTS-13, 
causing TTP, can either be congenital, 
idiopathic, or acquired as a result of 
autoantibodies, drugs, or malignancies 
(Trachtman, 2013). TTP can occur 
spontaneously or be triggered by an 
infection, pregnancy, or other stimulus of 
autoantibodies and as many as 30% of 
those affected relapse after a remission 
(Rosove, 2014).  Most commonly occurring 
in adults, primarily women, patients 
typically present with thrombocytopenia 
(with or without signs of bleeding), 
hemolytic anemia, fever, altered mental 
status or headaches, renal impairment, and 
abdominal or chest pain (Kappler et al, 
2014). Treatment for TTP is plasma 
exchange therapy, with the goal of 
replacing the missing ADAMTS-13 and 
removing the contributing antibody 
(Kappler et al., 2014).  Patients presenting 
with these symptoms may be cared for in 
many areas of practice and because correct 
diagnosis and prompt treatment are crucial 
in TTP, clinicians must be informed on 
signs, symptoms, and proper treatment. 
Without prompt recognition and treatment, 
mortality rates from TTP can be as high as 
90% (Kappler et al., 2014).  
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Platelets play a significant role in the formation of clots and the prevention of bleeding. 
The  normal platelet count falls within the range of 150,000 to 450,000/mm3 
(KonkleH,auser, Longo, Jameson, & Loscalzo, 2015). When endovascular tissue is injured 
platelets adhere to the intimal surface via binding with vWF, present in both endothelial 
tissue and plasma, and intercellular signals leading to activation of platelet glycoprotein 
llb/llla receptor and platelet aggregation (Konkle et al., 2015) Usually vWF is cleaved 
into smaller proteins by a plasma metalloprotease called a disintegrin and 
metalloproteinase with a thrombospondin type 1 motif member 13, or ADAMTS-13. In 
TTP however, the ADAMTS-13 concentration is very low either due to congenital 
abnormalities or acquired autoantibodies, which leaves large un-cleaved multimers of 
vWF that stimulate large aggregates of platelets, which can break off and occlude 
vessels (Rosove, 2014). Aggregation of platelets leads to organ damage and can result in 
neurologic, cardiac, and renal complications as well as bleeding complications. TTP is 
more common in pregnant women, patients with HIV infection, and can be induced by 
certain drugs or in patients who have undergone an organ or stem cell transplant 
(Konkle et al., 2015, Rosove, 2014) 
Significance of Pathophysiology 
The acute state of widespread microvascular thrombi and thrombocytopenia can lead to 
significant injury and precipitate poor outcomes for patients diagnosed with TTP. Patients 
are at risk for myocardial infarctions, cerebral vascular accidents, kidney failure, and other 
organ failure as a result of microvascular thrombi and ischemia. The thrombi that 
accumulate in TTP are mostly platelets and do not include fibrin which differentiates TTP 
from DIC  (Strecker-McGraw & Mark Andrew, 2011). The microvascular thrombi cause red 
blood cells to become injured and the result is hemolytic anemia without red cell 
antibodies (negative DAT/direct Coombs’ test) and the presence of schizocytes, or 
fragmented red blood cells (Strecker-McGraw & Mark Andrew, 2011). Therapy with 
plasma exchange as soon as possible is recommended to replace the ADAMTS-13 and 
reduce the antibodies associated with its destruction (Kappler et al, 2014).  Platelet 
transfusion in the setting of thrombocytopenia in patients with TTP is generally 
contraindicated and has been historically associated with an increase in mortality, 
although one recent retrospective study concluded that patients who received platelet 
transfusions did not have an increased risk of death as a result of the transfusions (Otrock, 
Liu, & Grossman, 2015).  
Nursing care must be directed at 
frequent assessment of patient 
symptoms, prevention of bleeding, 
infection, and supportive care. Careful 
monitoring of neurologic, cardiac and 
renal function as well as pain patterns 
and even slight changes in assessment 
criteria must be reported. 
Pharmacologic therapy may include 
corticosteroids, immune suppressing 
medications, and blood pressure 
regulators. Refractory patients may 
receive treatment with rituximab 
infusions, which requires careful 
management and close monitoring for 
reactions. Blood transfusions may be 
indicated for anemia or platelet 
products for bleeding may be used. 
Central venous access is often used for 
plasma exchange therapy and can be 
associated with bleeding and infection. 
Pain control and symptom management 
associated with widespread 
microvascular thrombi is important.  
TTP is a challenging and dangerous 
disorder that requires prompt 
recognition and treatment. The recent 
discovery of the ADAMTS-13 deficiency 
and increased availability of plasma 
exchange therapy has greatly increased 
an individual’s chance of surviving a TTP 
diagnosis.  Recognizing the differences 
in the microangiopathy disorders can 
assist clinicians in initiating the proper 
treatment for these patients. 
Diagnosing and treating TTP would be a 
significant responsibility, especially 
because successful identification and 
treatment of a disorder like TTP can 
save someone’s life. 
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